Ypsomed semi-annual results 2015/16: report and press release

Press Releases Ypsomed Group

Burgdorf – Ypsomed increases EBIT margin in double digits and raises the forecast for the business year 2015/16 clearly.

Lees meer...

Ypsomed signs master agreement for range of injection systems

Press Releases Ypsomed Group

Burgdorf – Hanmi Pharmaceutical Co., Ltd. has three biotechnology proteins in its project portfolio that are in various stages of development and approval. Ypsomed signs comprehensive master agreement with the South Korean Hanmi Pharmaceutical Co., Ltd. for pen systems and autoinjectors for three long-acting biologics.

Lees meer...

Ypsomed doubles dividends to shareholders

Press Releases Ypsomed Group

Burgdorf – For the 2014/15 fiscal year, a dividend of CHF 0.60 per share, exempt from withholding tax, will be paid to shareholders from capital reserves.

Lees meer...

Ypsomed now supplies the YpsoPen in Poland

Press Releases Ypsomed Group

Burgdorf – Ypsomed now supplies the Polish company Polfa Tarchomin S. A. with its reusable and affordable YpsoPen. The YpsoPen is being introduced to the Polish market and will be used to administer Polfa Tarchomin's insulin. Negotiations are in place to expand cooperation to other countries.

Lees meer...

Ypsomed 2014/15 business year: report and press release

Press Releases Ypsomed Group

Burgdorf – In business year 2014/15 Ypsomed Group posted consolidated sales of CHF 306.6 million, which represents an increase of 11% year on year.

Lees meer...